Biocon Biologics partners with Sandoz for distribution of its biosimilar to treat immune-related diseases in Japan
时间:2024-06-26 07:15:56 阅读(143)
Biocon Biologics Ltd on Friday signed a Distribution Agreement with Sandoz, granting the Company the exclusive rights to promote, sell and distribute th injection of Adalimumab BS in Japan.
“Based on this Agreement, Viatris has completed marketing and promotion of the product as of December 15, 2023, but will continue to provide transition support until Sandoz will gradually assume responsibilities for the product starting February 15, 2024. Biocon Biologics has acquired the global biosimilars portfolio of Viatris including Adalimumab. Fujifilm Kyowa Kirin Biologics Co. Ltd., the developer of the drug, has concluded an exclusive global marketing license agreement with Biocon Biologics Ltd affiliate,” the company said in a statement.
“Sandoz is committed to further strengthening its product pipeline to drive sustainable business growth,” it added.
The transfer of the distribution rights of this product is part of this strategy, and its addition to the product portfolio will strengthen Sandoz’s immunology and biosimilar portfolio.
Biocon Biologics recently announced the successful completion of its integration of the acquired Viatris’ biosimilars business in 120 countries ahead of schedule, marking a significant milestone in the Company’s journey as a fully integrated, global biosimilars enterprise. At a global level, Biocon Biologics has a robust pipeline of 20 assets for diabetology, oncology, immunology, and ophthalmology.
上一篇:SAT sets aside Sebi’s Rs 25-crore fine on Ambani brothers
下一篇:Year Ender 2023- Why ed-tech startups need to press the reboot button
猜你喜欢
- F&O expiry outlook September 1- If Nifty breaks 17350, long unwinding may pull index lower, caution advised
- European shares fall for seventh day; focus on US CPI data
- Petrol, Diesel Price Today, 8 Nov 2022- Fuel rates unaltered; check prices in Delhi, Mumbai, other cities
- Europe mulls shorter T+1 settlement cycle
- Elevation Capital to sell stake worth $125 million in NSE
- Explainer- Sebi’s plan to cut IPO listing to 3 days
- Petrol, Diesel Price Today, 22 Sep 2022- Fuel cost steady; check rates in Delhi, Mumbai, Noida, other cities
- Rupee rises 14 paise to close at 82
- Petrol and Diesel Rate Today, 5 March- Fuel prices steady; Check rates in Delhi, Mumbai, other cities